GeoVax Advances Gedeptin Toward Phase 2 Initiation and Strategic Partnership Opportunities
GeoVax Labs outlines near-term milestones for its oncology candidate Gedeptin, including a planned Phase 2 trial in head and neck cancer, as it seeks combination therapy partnerships.
GeoVax Labs, Inc. (Nasdaq: GOVX) today detailed its development strategy for Gedeptin, a gene-directed enzyme prodrug therapy, as the company prepares to initiate a Phase 2 clinical trial and explore strategic collaborations. The announcement underscores the growing emphasis on combination regimens in oncology, where Gedeptin could be integrated with immune checkpoint inhibitors and other standard treatments.
GeoVax is targeting a Phase 2 trial initiation in 2027 for Gedeptin combined with an immune checkpoint inhibitor as a first-line neoadjuvant treatment for patients with resectable locally advanced head and neck cancer. The study will evaluate tumor response, biomarker-driven immune activation, and event-free survival. This trial is seen as a critical step to validate Gedeptin's role in combination immuno-oncology strategies.
Beyond head and neck cancer, the company plans to expand preclinical and translational work to identify additional solid tumor indications where Gedeptin could provide clinical benefit. This broader exploration aims to support future development and partnership opportunities.
GeoVax is actively pursuing clinical development partnerships, combination-focused collaborations, and potential licensing or co-development deals. David A. Dodd, Chairman and CEO, stated, “We are entering an important phase of development for Gedeptin, with a focus on clinical execution and advancing discussions around potential partnerships. As combination therapy becomes more common across oncology, we believe Gedeptin is well positioned to be integrated into these regimens and contribute to improved treatment outcomes.”
The company has established a foundation for Gedeptin's advancement, including completed Phase 1/2 clinical experience in advanced head and neck cancer, an Oncology Advisory Board with immuno-oncology expertise, and expanded intellectual property covering combination use with checkpoint inhibitors. This foundation supports both continued clinical progression and engagement with potential partners.
Gedeptin is a gene-directed enzyme prodrug therapy delivered intratumorally using a non-replicating viral vector encoding purine nucleoside phosphorylase. After systemic prodrug administration, the enzyme converts the prodrug into a cytotoxic agent within the tumor microenvironment. GeoVax's broader pipeline includes GEO-MVA, a vaccine for mpox and smallpox advancing toward a pivotal Phase 3 trial in 2026, and GEO-CM04S1, a COVID-19 vaccine candidate for immunocompromised populations.
For more information, visit www.geovax.com.